Study of Plozasiran in Adults With Severe Hypertriglyceridemia
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 311 participants.
Also called NCT06347016
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 311 participants
- Sponsor
- Registry
-
NCT06347016 -
2023-509301-80
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- United States, Argentina, Brazil, Bulgaria, Canada, Czechia, France, Germany, Hungary, Latvia, Lithuania, New Zealand, Poland, Slovakia, South Africa, Spain
- Registry status
- Completed
Technical summary
Registry record NCT06347016. Randomized; quadruple masking; primary purpose treatment. Start 2024-07-23 (actual); primary completion 2026-06-17 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Study of Plozasiran in Adults With Severe Hypertriglyceridemia
- Acronym
- SHASTA-4
- Condition
- Severe Hypertriglyceridemia
- Intervention (Drug)
- Plozasiran Injection
- Intervention (Drug)
- Placebo
- Lead sponsor
- Arrowhead Pharmaceuticals
Record details
- Record id
cardio:ct-nct06347016- Content hash
4ac1041e73dab5d9becbc469e5f03a9baffdbb7f8efcea1fbbe2ff9d8c061ada